drugset / Trial / NCT01397734
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Phase 1
Terminated
7 enrolled
Beth Israel Deaconess Medical Center
National Institutes of Health (NIH) · collabTeva Pharmaceuticals USA · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
Timeline
- Start
- 2011-09
- Primary completion
- 2018-08-06
- Completion
- 2018-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |